Regression of Autoimmune Gastritis after Eradication of Helicobacter pylori

We report a case of autoimmune gastritis (AIG) in which gastric mucosal atrophy improved with Helicobacter pylori eradication. Based on endoscopic findings (advanced gastric atrophy with vascular visibility and diffuse redness in remnant oxyntic mucosa), a woman in her 40s was suspected of having AI...

Full description

Saved in:
Bibliographic Details
Published inCase reports in gastroenterology Vol. 17; no. 1; pp. 34 - 40
Main Authors Kotera, Tohru, Nishimi, Yurika, Kushima, Ryoji, Haruma, Ken
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger AG 01.01.2023
The Author(s). Published by S. Karger AG
Karger Publishers
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:We report a case of autoimmune gastritis (AIG) in which gastric mucosal atrophy improved with Helicobacter pylori eradication. Based on endoscopic findings (advanced gastric atrophy with vascular visibility and diffuse redness in remnant oxyntic mucosa), a woman in her 40s was suspected of having AIG coexisting with an active H. pylori infection. This was confirmed by a positive anti-parietal cell antibody (PCA, 1:160), an elevated serum gastrin level (638 pg/mL), and positive anti-H. pylori antibody (Hp Ab, 15.5 U/mL) and H. pylori stool antigen tests. Seven months after eradication, reduced vascular visibility and disappearance of diffuse redness on endoscopy and reduced PCA (1:40) and Hp Ab (5.1 U/mL) titers were observed, although histopathological findings (basal-predominant lymphocytic infiltration, destruction of parietal and chief cells, pseudopyloric metaplasia, and enterochromaffin-like cell hyperplasia) were consistent with AIG. Endoscopy 26 months after eradication showed further improvement in atrophic findings in the gastric corpus and histopathological recovery of parietal and chief cells in fundic glands. Serum gastrin levels returned to normal (64 pg/mL), and the PCA titer fell further (1:20).
ISSN:1662-0631
1662-0631
DOI:10.1159/000528388